P1.04-27 Processing Escapes: Novel Resistance Mechanisms Under Immune Checkpoint Inhibition in NSCLC
Michael Wessolly(Essen University Hospital), Thomas Mairinger(Helios Klinikum Emil von Behring), Jan Schmeller(Deutsches Konsortium für Translationale Krebsforschung), Fabian Mairinger(University of Duisburg-Essen), Kurt Werner Schmid(Essen University Hospital), Sabrina Borchert(Essen University Hospital), Jens Kollmeier(Helios Klinikum Emil von Behring), Anna Streubel(Helios Klinikum Emil von Behring), Robert Walter(Ruhrlandklinik), Elena Mairinger(University of Duisburg-Essen), Wilfried Eberhardt(National Center for Tumor Diseases), Torsten Blum(MSB Medical School Berlin), R A Werner(Helios Klinikum Emil von Behring), Susann Stephan-Falkenau(Helios Klinikum Emil von Behring), S Griff(Helios Klinikum Emil von Behring), Torsten Bauer(Helios Klinikum Emil von Behring)
Cited by 0
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin
|Biochemical and Biophysical Research Communications|1985|987
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872